Coherus Oncology develops and sells LOQTORZI, a cancer medicine, and is developing two other cancer treatment candidates in clinical studies. It last closed at $0.37 on Nov 20, down 4.47% on the day. The next earnings report for CHRS is expected around Tue, Jan 12, 2027. For the quarter ended Sep 2026, CHRS reported EPS of -$0.25 on revenue of $14.3M, with revenue up 23.4% from a year ago. Over its last 8 reports the stock moved an average of 10.9% the session after earnings.
AI Auto Pilots
Is CHRS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CHRS.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CHRSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CHRS · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 91% below its 20 day and 161% below its 50 day average. It is 285% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the 52 week low at $0.36, and the nearest resistance the Pivot at $0.38.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 21.8%/day
Key levels
$2.6252 week high+608.1%
$1.42200 day average+283.8%
$1.18100 day average+218.9%
$1.09Swing high (Oct 15)+194.6%
$0.9750 day average+162.2%
$0.7120 day average+91.9%
$0.40Pivot R1+8.1%
$0.38Pivot+2.7%
$0.37Last close
$0.3652 week low−2.7%
$0.35Pivot S1−5.4%
Indicators
RSI (14)
23.15
Oversold below 30
Oversold
MACD
-0.17
Below its signal line
Bearish
Stochastic
1.7
Near the bottom of its range
Oversold
ADX (14)
37.4
Trending down
Williams %R
-98.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-117.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−52.0%
Change over 10 sessions
Bearish
ATR (14)
$0.08
Typical daily range, 21.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 58.4%/day
Key levels
$2.6252 week high+608.1%
$1.42200 day average+283.8%
$1.18100 day average+218.9%
$1.09Swing high (Oct 15)+194.6%
$0.9750 day average+162.2%
$0.7120 day average+91.9%
$0.40Pivot R1+8.1%
$0.38Pivot+2.7%
$0.37Last close
$0.3652 week low−2.7%
$0.35Pivot S1−5.4%
Indicators
RSI (14)
21.13
Oversold below 30
Oversold
MACD
-0.24
Below its signal line
Bearish
Stochastic
2.6
Near the bottom of its range
Oversold
ADX (14)
27.4
Trending down
Williams %R
-99.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-214.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−72.2%
Change over 10 sessions
Bearish
ATR (14)
$0.22
Typical daily range, 58.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CHRS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CHRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow CHRS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CHRSHow many large options trades hit CHRS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CHRS in the last 90 days.
From SEC Form 4 filings by CHRS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CHRS is in one of them and how their past CHRS trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Coherus Oncology
Coherus Oncology is a cancer drug company based in Redwood City, California. Its main product is LOQTORZI, an antibody medicine that blocks the PD-1 pathway. It is approved in the United States for nasopharyngeal carcinoma, a cancer of the upper throat, and the company sells it for treating cancer patients. The company is also developing two other cancer treatment candidates in clinical studies, aimed at cancers such as liver, head and neck, and colorectal cancer.